阿昔单抗诱发的迟发性严重血小板减少症。
Abciximab-induced delayed profound thrombocytopaenia.
作者信息
Jbara Manar, Bhogal Sukhdeep, Bajaj Kailash, Chhabra Lovely
机构信息
Department of Internal Medicine, East Tennessee State University, Johnson City, Tennessee, USA.
East Tennessee State University, Kingsport, Tennessee, USA.
出版信息
BMJ Case Rep. 2017 Jun 2;2017:bcr-2017-219379. doi: 10.1136/bcr-2017-219379.
Abciximab, the first approved glycoprotein (GP IIb/IIIa) inhibitor, is being widely used during acute coronary syndromes and offers the promising approach to antithrombotic therapy. We present a case of a young woman who initially received abciximab infusion for undergoing percutaneous coronary intervention of left anterior descending artery and was eventually diagnosed with abciximab-induced delayed thrombocytopaenia. This case outlines the importance of close follow-up of these patients to prevent serious adverse events.
阿昔单抗是首个获批的糖蛋白（GP IIb/IIIa）抑制剂，在急性冠脉综合征期间被广泛使用，为抗血栓治疗提供了有前景的方法。我们报告一例年轻女性病例，该患者最初因接受左前降支经皮冠状动脉介入治疗而输注阿昔单抗，最终被诊断为阿昔单抗诱导的延迟性血小板减少症。该病例强调了对这些患者进行密切随访以预防严重不良事件的重要性。
Zotero 插件